Tom O’Brien

The Takeovers Panel has found Cosette cannot close a Mayne Pharma drug manufacturing plant in Adelaide, another win for Mayne in its push to block the US drug maker from walking away from their $672 million merger.

The Takeovers Panel has agreed to hear Mayne Pharma's latest dispute with Cosette over the US drug maker's attempts to walk away from their $672 million merger agreement and extended the timeline for completing the deal.

Mayne Pharma has secured an extension of the deadline for securing Foreign Investment Review Board approval of its $672 million tie-up with US drug maker Cosette.

Cosette plans to appeal a ruling that rejected its bid to terminate an agreement to merge with Mayne Pharma, as the US drug company also refuses to agree to conditions needed to win Foreign Investment Review Board approval for the tie-up.

Mayne Pharma has won a dispute with US drug maker Cosette over the termination of a $672 million merger agreement, with a judge finding Mayne did not breach its continuous disclosure obligations by failing to disclose a letter from the US FDA sooner.

Insurers Bond & Credit Company and Tokio Marine can't eyeball advice given by Ashurst to lender White Oak in a dispute over the collapse of supply chain finance company Greensill.

Lender White Oak has argued it can shield an email that repeats legal advice from Ashurst that was accidentally disclosed to insurers Bond & Credit Company and Tokio Marine, which it has sued over the collapse of supply chain finance company Greensill. 

Engineering firm Clough Projects Australia is challenging a judge's order staying its $54 million cross-claim against former Energy Connection joint venture partner Elecnor.

Real estate asset manager Dexus wants information that the Asia Pacific Airport Corporation gave to several consultants in a court battle over allegations it breached a shareholder deed in selling a stake in the airport operator. 

Mayne Pharma and US drug maker Cosette have agreed to postpone the start of trial in a case over the termination of a $672 million merger to allow for late amendments.